NASDAQ:VRUS - Pharmasset Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0041 0.00 (0.00 %) (As of 02/18/2019 10:59 AM ET)Previous Close$0.0040Today's Range$0.0030 - $0.004152-Week Range$0.0008 - $0.0112Volume13.78 million shsAverage Volume15.14 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc. Receive VRUS News and Ratings via Email Sign-up to receive the latest news and ratings for VRUS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:VRUS Previous Symbol CUSIPN/A WebN/A Phone+1-609-6134100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A OptionableNot Optionable Pharmasset (NASDAQ:VRUS) Frequently Asked Questions What is Pharmasset's stock symbol? Pharmasset trades on the NASDAQ under the ticker symbol "VRUS." Has Pharmasset been receiving favorable news coverage? Headlines about VRUS stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pharmasset earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. How do I buy shares of Pharmasset? Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pharmasset's stock price today? One share of VRUS stock can currently be purchased for approximately $0.0041. How can I contact Pharmasset? Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100. MarketBeat Community Rating for Pharmasset (NASDAQ VRUS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 128 (Vote Outperform)Underperform Votes: 109 (Vote Underperform)Total Votes: 237MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: What is the Bid-Ask Spread?